BioSpace News Archive

Coya Therapeutics, Inc. (“Coya” or the “Company”) (Nasdaq: COYA) today announced the closing of its initial public offering of 3,050,000 shares of its com mon stock and accompanying warrants to purchase up to 1,525,000 shares of common stock.

Sotera Health Company announced that Chairman and CEO Michael B. Petras, Jr. will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 pm Eastern.

Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 4:30 p.m. ET.

Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 2 new employees inducement stock options to purchase an aggregate of 12,650 common shares, at a per share exercise price of $5.94, the closing price of Aurinia’s common stock on January 3, 2023, and an aggregate of 7,730 inducement restricted stock units.

ADC Therapeutics SA announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer, effective January 3, 2023. He will serve on the Company’s executive leadership team.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted inducement awards to two new non-executive employees.

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will participate at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 at 5:15 p.m. EST.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) announces that TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA).

MedMira Inc. announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection -, in the special edition of Pathogens by MDPI, a Swiss based medical journal.